Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis

Michael W. Lark, George B. Stroup, Shing Mei Hwang, Ian E. James, David J. Rieman, Fred H. Drake, Jeremy N. Bradbeer, Ashwini Mathur, Karl F. Erhard, Kenneth A. Newlander, Stephen T. Ross, Kevin L. Salyers, Brian R. Smith, William H. Miller, William F. Huffman and Maxine Gowen
Journal of Pharmacology and Experimental Therapeutics November 1999, 291 (2) 612-617;
Michael W. Lark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George B. Stroup
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shing Mei Hwang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian E. James
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Rieman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred H. Drake
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy N. Bradbeer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashwini Mathur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl F. Erhard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth A. Newlander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen T. Ross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Salyers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian R. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William H. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William F. Huffman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxine Gowen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The Arg-Gly-Asp (RGD)-binding integrin αVβ3is highly expressed on osteoclasts and has been proposed to mediate cell-matrix adhesion required for osteoclast-mediated bone resorption. Antagonism of this receptor should prevent stable osteoclast adhesion and thereby inhibit bone resorption. We have generated an orally bioavailable, nonpeptide RGD mimetic αvβ3antagonist, SB 265123, which prevents bone loss in vivo when dosed by oral administration. SB 265123 binds αvβ3and the closely related integrin αvβ5 with high affinity (Ki = 3.5 and 1.3 nM, respectively), but binds only weakly to the related RGD-binding integrins αIIbβ3(Ki >1 μM) and α5β1 (Ki >1 μM). The compound inhibits αvβ3-mediated cell adhesion with an IC50 = 60 nM and more importantly, inhibits human osteoclast-mediated bone resorption in vitro with an IC50 = 48 nM. In vivo, SB 265123 completely blocks bone resorption in a thyroparathyroidectomized rat model of acute bone resorption when dosed at 2.5 mg/kg/h by continuous i.v. infusion. When dosed orally with 3 to 30 mg/kg b.i.d., in the ovariectomy-induced rat model of osteoporosis, SB 265123 prevents bone resorption in a dose-dependent fashion. This is the first report of an orally active αvβ3 antagonist that is effective at inhibiting bone resorption when dosed in a pharmaceutically acceptable fashion. Such a molecule may provide a novel therapeutic agent for the treatment of postmenopausal osteoporosis.

Footnotes

  • Send reprint requests to: Michael W. Lark, UW2109, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA. E-mail: michael_lark-1{at}sbphrd.com

  • Abbreviations:
    TPTX
    thyroparathyroidectomized
    ovx
    ovariectomized
    PTH
    parathyroid hormone
    BMD
    bone mineral density
    • Received April 27, 1999.
    • Accepted June 22, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 291 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 291, Issue 2
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis

Michael W. Lark, George B. Stroup, Shing Mei Hwang, Ian E. James, David J. Rieman, Fred H. Drake, Jeremy N. Bradbeer, Ashwini Mathur, Karl F. Erhard, Kenneth A. Newlander, Stephen T. Ross, Kevin L. Salyers, Brian R. Smith, William H. Miller, William F. Huffman and Maxine Gowen
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 612-617;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis

Michael W. Lark, George B. Stroup, Shing Mei Hwang, Ian E. James, David J. Rieman, Fred H. Drake, Jeremy N. Bradbeer, Ashwini Mathur, Karl F. Erhard, Kenneth A. Newlander, Stephen T. Ross, Kevin L. Salyers, Brian R. Smith, William H. Miller, William F. Huffman and Maxine Gowen
Journal of Pharmacology and Experimental Therapeutics November 1, 1999, 291 (2) 612-617;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics